

## Starpharma's nasal spray effective against influenza A & B virus

23 May 2022 | News

**VIRALEZE is registered in more than 30 countries, including in Europe, the UK, Middle East, and Asia**

Australia-based Starpharma has announced that SPL7013, the antiviral agent in VIRALEZE nasal spray, achieved 95% and 99.7% reduction in viral infectivity against two significant types of influenza virus, A and B, respectively, in virucidal assays.

The virucidal assays conducted at the Scripps Research Institute in the US assessed the irreversible nature of the effect of a compound against viruses.

In addition to testing the virucidal activity of SPL7013, the Scripps testing assessed the activity of two antiviral agents used in widely available nasal sprays - hydroxypropyl methyl cellulose (HPMC) and iota-carrageenan. In contrast to the potent and rapid effect of SPL7013, HPMC and iota-carrageenan did not exhibit virucidal effect in this experiment, even after 30 minutes.

The antiviral activity of SPL7013 in other pandemic-causing influenza A viruses has previously been reported by Starpharma, with SPL7013 demonstrating potent antiviral activity against H1N1 (Swine Flu) and H3N2 (Avian Flu).

These new virucidal findings are consistent with the previously reported activity of SPL7013 against multiple variants of SARS-CoV-2, including Delta, Alpha, Beta, Gamma, and Omicron, as well as other respiratory viruses that cause the common cold. The broad-spectrum antiviral and virucidal activity of SPL7013 (VIRALEZE), which encompasses all of the pandemic-causing respiratory viruses, highlights the opportunities for VIRALEZE in combatting seasonal flu epidemics as well as pandemic preparedness.